

# [Pillar launches OncoReveal Nexus NGS assay](#)

written by CAP TODAY

August 28, 2024

Aug. 28, 2024—[Pillar Biosciences](#) has announced the global launch of OncoReveal Nexus, a research use only next-generation sequencing kit designed to assess key driver genes for hematological and solid tumor malignancies in one multiplex reaction. The assay can batch up to 81 patient samples in a single Illumina MiSeq sequencing run, using as little as 2.5 ng DNA per sample, and has a sample-to-report time of two to three days after DNA isolation.

Memorial Sloan Kettering Cancer Center has received New York State Department of Health approval for clinical implementation of the assay and will be the first to utilize it. At MSK, the panel will be branded MSK-REACT and is expected to help accelerate genomic results in parallel with the comprehensive genomic profiling assay MSK-IMPACT.



©2026 CAP TODAY, all rights reserved.